Europe's Committee for Medicinal Products for Human Use has signed off on Novo Nordisk's one-weekly insulin for diabetes patients, in addition to providing positive opinions on Novartis' Fabhalta and Pfizer's antibiotic combo Emblaveo. Sales are booming for Novo Nordisk’s GLP-1 treatments for diabetes and obesity. But that doesn’t mean the Danish company has moved on from its previous generation of blood sugar modulators. Though it’s been on the market for a century, there are still advances to be made with good old insulin. With a positive recommendation from Europe’s Committee for Medicinal Products for Human Use (CHMP), Novo has come a step closer to bringing its revolutionary Awiqli (once-weekly basal insulin icodec) to the market. The treatment has been tested successfully in both Type 1 and Type 2 diabetes patients. “The world has never seen a weekly insulin,” Novo CEO Lars Fruergaard Jørgensen told Fierce Pharma in August of 2021. Less than three years later, it's close to arriving. The company expects the FDA to sign off on Awiqli next month and to get a nod in Europe by the end of May. By reducing the frequency of dosing, Awiqli could improve convenience, adherence and quality of life. “Awiqli has the potential to become the insulin of choice for people with type 2 diabetes initiating insulin treatment," Martin Holst Lange, Novo’s EVP for development, said in a release. The positive CHMP opinion is based on results from six phase 3 studies of 4,000 patients. In people with Type 2 diabetes, Awiqli achieved superior blood sugar reduction and time spent within a recommended blood sugar range compared with daily basal insulin. CHMP says "yes" to other new drugs
Astellas gets thumbs-up for Xtandi expansion The FDA signed off on Xtandi in the indication in November. Astellas hopes for a marketing authorization endorsement in Europe by the end of May.